Patent Application
20230383017
The invention relates to the field of fillers. More particularly, the invention relates to cross-linked hyaluronic acid beads for use in fillers and a process for preparing such hyaluronic acid beads.
hyaluronic acid (HA) is a linear macromolecular polysaccharide consisting of alternately bonded b-D-N-acetylglucosamine and b-D-glucuronic acid. It is well known to inject hyaluronic acid under the dermis for cosmetic reasons. Such dermal fillers can be used to offset the effects of aging on the skin, by smoothing soft tissue defects like nasolabial folds and marionette lines as well as more substantial augmentation such as smoothing hollow cheeks resulting from lipoatrophy, or enhancing the fullness of lips. It is also known to use HA as a filler for body sculpting.
Chemical cross-linking of HA is often necessary in order to increase the durability of the implant, since unmodified HA generally has a half-life in the dermis of only a day or two. HA with high levels of cross-linking tend to elicit a foreign body reaction, which stimulates the deposition of collagen around the foreign particle. Collagen deposition is desired if a long-lasting filler effect is sought. However, too much foreign body reaction causes inflammation and other related problems. Dermal fillers completely composed of HA with high levels of cross-linking tend to cause such problems.
Further, if an HA-based dermal filler is ever accidentally injected into a blood vessel, the blood vessel may be occluded by the dermal filler. If such an occlusion cannot be promptly removed, necrosis may result.
Forming one aspect of the invention is a process for preparing hyaluronic acid (HA) beads including the steps of combining an HA compound with sodium hydroxide, forming an HA solution and injecting the HA solution into an oil solution, forming an emulsion with HA beads.
In some embodiments, the process further includes adding a cross-linking reagent to the HA beads, forming a bead mixture and stirring the bead mixture for 24 hours in room temperature, thereby forming cross-linked HA beads.
Alternatively, in other embodiments, the process further includes adding a cross-linking reagent to the HA solution prior to the injecting and stirring the emulsion for 24 hours in room temperature after the injecting, thereby forming cross-linked HA beads.
Forming another aspect of the invention is a hyaluronic acid (HA) bead for use in a dermal filler, the bead being cross-linked and adapted to dissolve in vivo upon contact with hyaluronidase.
Forming another aspect of the invention is a filler including hyaluronic acid with a predetermined level of cross-linking, and hyaluronic acid beads suspended in the hyaluronic acid, the hyaluronic acid beads having a cross-linking level higher than that of the hyaluronic acid, the hyaluronic acid beads cross-linked and adapted to dissolve in vivo upon contact with hyaluronidase.
Reference will now be made to the attached drawings, when read in combination with the following detailed description, wherein like reference numerals refer to like parts throughout the several views, and in which:
With reference to the attached illustrations, a non-limiting exemplary embodiment of an improved filler, of hyaluronic acid (HA) beads for use in the filler, and of processes 200, 300 for forming the HA beads will be discussed. The HA beads and filler will first be described, then processes 200, 300.
The hyaluronic acid beads are globules of hyaluronic acid that are cross-linked and will naturally degrade in about 9 months when injected into a patient. The HA beads are typically 80-150 microns in diameter. According to a first embodiment, the HA beads are generally spherical and translucent. According to a second embodiment, the HA beads are perfectly spherical and transparent.
The HA beads are also adapted to dissolve in vivo in 20 minutes upon contact with hyaluronidase.
A microscope enzyme degradation study was performed on the cross-linked HA beads of the present invention to demonstrate this characteristic.
In the study, 10 microliters of an HA bead suspension in phosphate buffered saline (PBS) was placed on a dimpled glass microscope slide and 100 microliters of 165 units/mL, of hyaluronidase, which is also suspended in PBS, was added and mixed in with a stainless steel wire.
More PBS was added to fill the dimple in the slide and a cover slip was carefully placed over the sample to avoid the entrapment of bubbles. Mineral oil was deposited around the edges of the cover slip to seal and prevent evaporation.
The slide was placed on a temperature controlled microscope stage set to 37 Celsius and digital micrographs were acquired periodically. The magnification of the microscope was set to 25 times (the beads are 80-150 microns in diameter).
Whereas a specific embodiments of the HA bead are herein shown and described, variations are possible. In some examples, the HA beads have a diameter of 1 to 1000 microns.
The filler of the present invention comprises hyaluronic acid with a predetermined level of cross-linking. The improvement of the filler comprises the HA beads described above suspended in hyaluronic acid. The predetermined level of cross-linking of the hyaluronic acid is lower than the level of cross-linking of the HA beads suspended therein.
The filler is made by dissolving HA in a sodium hydroxide solution. BDDE is then added and mixed into the solution. The resulting mixture is warmed and further mixed for a period of time. It is then cooled and neutralized with acid. The resulting gel mixture is diluted as appropriate and then milled into small particles. The gel particles are washed by dialysis. The HA beads, described above, and produced separately, are blended in under low shear. Whereas a specific embodiment of the filler are described, variations are possible.
In some examples, rather than suspending the HA beads have a cross-linking level that is higher than the predetermined level of cross-linking of the hyaluronic acid, the HA beads would have a cross-linking level that is lower than that of the hyaluronic acid.
In some examples, rather than suspending the HA beads in hyaluronic acid, the filler may be composed entirely of the cross-linked HA beads described above.
Referring to
At 204, one milliliter of the HA solution is injected into 5 mL of a stirred oil solution using a 22 gauge syringe needle at a rate of 1 mL/min. The oil solution comprises an emulsifier, 2% Tween-80, in isobutanol and is stirred at 1500 rotations per minute with an overhead stirrer having an anchor shaped paddle. The stirring is maintained for 1 minute after the HA solution is injected into the oil solution. The separation of the HA solution and oil solution forms an emulsion with HA beads.
While the emulsion is stirred at 204, the emulsion is drained into 50 mL of another stirred solution containing 2% Tween-80 in dry ethanol, the dry ethanol being stirred at 1100 rotations per minute with a magnetic stirrer. This ethanol mixture is then stirred for at least another five minutes.
At 206, the resulting HA beads are collected by vacuum filtration through a sintered glass and fritted funnel. The HA beads are then washed multiple times with ethanol, washed once with hexanes, and then dried.
At 208, the HA beads are cross-linked. The isolated HA beads are suspended in dry ethanol, and a stoichiometric amount of potassium hydroxide is added along with a cross-linking reagent forming a bead mixture. In this case, 1,4-butanediol diglycidyl ether (BDDE) is added in a BDDE:HA mass ratio of 1:5.
At 210, the bead mixture is stirred for 24 hours at room temperature, thereby cross-linking the HA beads.
The cross-linked HA beads are collected at 212 as before, by vacuum filtration through a sintered glass and fritted funnel. The cross-linked beads are further washed multiple times with ethanol, washed once with hexanes, and then dried.
Whereas a specific embodiment of process 200 is described, variations are possible.
In some examples, at 204, rather than draining the emulsion into 50 mL of a dry ethanol solution, the emulsion may be drained into a solution containing a different alcohol, such as methanol, propanol, or isopropanol.
Further, in other examples, at 206 and/or 212, the HA beads and/or cross-linked HA beads may be washed with a different alcohol, such as methanol, propanol, or isopropanol, and then washed once with a volatile lipophilic solvent other than hexane.
At 304, the HA solution is chilled in an ice bath.
While chilling the HA solution, 300 pL of a cross-linking reagent, BDDE in this case, is mixed well into the HA solution at 306.
At 308, the resulting HA solution with BDDE is then injected into 15.0 mL of a stirred oil solution using a 16-gauge needle at a rate of 1 mL/min. The oil solution comprises an emulsifier, 5% SPAN-80, in heavy mineral oil and is stirred at 800 rotations per minute. The separation of the HA solution and oil solution forms an emulsion with HA beads.
At 310, the emulsion is stirred for 24 hours at room temperature, thereby cross-linking the HA beads.
After the stirring step, at 312, 3.00 mL of a neutralizer is added to the emulsion. The neutralizer has a composition as set out below:
The cross-linking reaction is performed at very high pH. After cross-linking, the neutralizer lowers the pH to physiological levels and helps to stop any further reaction with unreacted cross-linking material.
The mixture is further stirred for another 30 minutes and then 5 mL of hexanes is added in preparation for the collecting and washing steps.
The cross-linked HA beads are collected at 314, by vacuum filtration using a coarse sintered glass Buchner funnel. The cross-linked HA beads are further rinsed multiple times with hexanes and air dried to remove most of the hexanes without drying out the beads.
The cross-linked HA beads are then washed once more with phosphate-buffered saline (PBS) and then dried.
Whereas a specific embodiment of process 300 is described, variations are possible.
In some examples, at 314, the cross-linked HA beads may be washed with a volatile lipophilic solvent other than hexane.
In some examples, at 312, a neutralizer having a different composition may be used.
An advantage of the present invention is that the HA beads can have an independent level of cross-linking relative to their surrounding substance. As such, when suspended in hyaluronic acid, the HA beads can have a cross-linking level different from that of the hyaluronic acid. As noted in the background, hyaluronic acid with high levels of cross-linking tend to elicit a foreign body reaction, which stimulates the deposition of collagen around the foreign particle. However, too much foreign body reaction causes inflammation and other related problems.
By suspending cross-linked HA beads with a high level of cross-linking in an HA dermal filler with low levels of cross-linking, for example, it will be possible to finely “tune” the dermal filler for a desired amount of foreign body reaction by tweaking the ratio of HA beads to hyaluronic acid in the filler.
Further, having a dispersion of highly cross-linked HA beads will allow the individual beads to be individually encapsulated with collagen rather than having a bolus of highly cross-linked gel being encapsulated. In such cases, collagen would tend to form around the periphery of the bolus.
An advantage of the filler that is entirely comprised of HA beads is that it helps to illicit less foreign body response. It was found that the solid, smooth, spherical particles of the described HA beads illicit less foreign body response than particles having sharp edges. The current milling process, which produces the gel particles for the base hyaluronic acid, creates gel particles with sharp edges.
Another advantage of the present invention is that the HA beads can be degraded in vivo within 20 minutes upon contact with a hyaluronidase enzyme.
The presently claimed cross-linked HA beads will naturally degrade in about 9 months when injected into a patient. However, if the HA beads are accidentally injected into a blood vessel, occlusion may result. The HA beads and the filler in the present invention, can be promptly dissolved by injecting a hyaluronidase enzyme solution, which is available by prescription, into the patient.
A yet further surprising advantage is the ability to inject, at relatively low extrusion forces, relatively large volumes of filler with relatively large particles; in this regard, it has been found that using a 16G needle, HA filler with an average of 2.55 MDa (molecular weight of 2,500,000 Daltons) with a standard deviation of 2.5% with 5 wt. % HA particles having an average diameter of 1000 microns and a standard deviation of 20% can be injected with only 0.5 pounds of pressure. This allows the filler to be used for body contouring purposes, such as breast augmentation.
Whereas a specific embodiments of the HA bead, filler and processes of making same are herein shown and described, variations are possible.
Accordingly, the invention should be understood to be limited only by the accompanying claims, purposively construed.
Having described my invention, other and additional preferred embodiments will become apparent to those skilled in the art to which it pertains, and without deviating from the scope of the appended claims. The detailed description and drawings are further understood to be supportive of the disclosure, the scope of which being defined by the claims. While some of the best modes and other embodiments for carrying out the claimed teachings have been described in detail, various alternative designs and embodiments exist for practicing the disclosure defined in the appended claims.
The foregoing disclosure is further understood as not intended to limit the present disclosure to the precise forms or particular fields of use disclosed. As such, it is contemplated that various alternate embodiments and/or modifications to the present disclosure, whether explicitly described or implied herein, are possible in light of the disclosure. Having thus described embodiments of the present disclosure, a person of ordinary skill in the art will recognize that changes may be made in form and detail without departing from the scope of the present disclosure. Thus, the present disclosure is limited only by the claims.
In the foregoing specification, the disclosure has been described with reference to specific embodiments. However, as one skilled in the art will appreciate, various embodiments disclosed herein can be modified or otherwise implemented in various other ways without departing from the spirit and scope of the disclosure. Accordingly, this description is to be considered as illustrative and is for the purpose of teaching those skilled in the art the manner of making and using various embodiments of the disclosure. It is to be understood that the forms of disclosure herein shown and described are to be taken as representative embodiments. Equivalent elements, materials, processes or steps may be substituted for those representatively illustrated and described herein. Moreover, certain features of the disclosure may be utilized independently of the use of other features, all as would be apparent to one skilled in the art after having the benefit of this description of the disclosure. Expressions such as “including”, “comprising”, “incorporating”, “consisting of”, “have”, “is” used to describe and claim the present disclosure are intended to be construed in a non-exclusive manner, namely allowing for items, components or elements not explicitly described also to be present. Reference to the singular is also to be construed to relate to the plural.
Further, various embodiments disclosed herein are to be taken in the illustrative and explanatory sense, and should in no way be construed as limiting of the present disclosure. All joinder references (e.g., attached, affixed, coupled, connected, and the like) are only used to aid the reader's understanding of the present disclosure, and may not create limitations, particularly as to the position, orientation, or use of the systems and/or methods disclosed herein. Therefore, joinder references, if any, are to be construed broadly. Moreover, such joinder references do not necessarily infer that two elements are directly connected to each other.
Additionally, all numerical terms, such as, but not limited to, “first”, “second”, “third”, “primary”, “secondary”, “main” or any other ordinary and/or numerical terms, should also be taken only as identifiers, to assist the reader's understanding of the various elements, embodiments, variations and/or modifications of the present disclosure, and may not create any limitations, particularly as to the order, or preference, of any element, embodiment, variation and/or modification relative to, or over, another element, embodiment, variation and/or modification.
It will also be appreciated that one or more of the elements depicted in the drawings/figures can also be implemented in a more separated or integrated manner, or even removed or rendered as inoperable in certain cases, as is useful in accordance with a particular application. Additionally, any signal hatches in the drawings/figures should be considered only as exemplary, and not limiting, unless otherwise specifically specified.
The present application claims the priority of PCT/CA2021/050164 filed Feb. 16, 2021.
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/CA2021/050164 | Feb 2021 | US |
| Child | 18233564 | US |
